awmsg logo



triptorelin (Decapeptyl® SR)


Reference No. 1658

Publication date:
14/03/2017


Appraisal information

triptorelin (Decapeptyl® SR) 22.5 mg powder and solvent for suspension for injection
triptorelin (Decapeptyl® SR) 11.25 mg powder for suspension for injection
triptorelin (Decapeptyl® SR) 3 mg powder for suspension for injection


Company: Ipsen Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 11/01/2017
AWMSG meeting date: 15/02/2017
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0417
Ministerial ratification: 14/03/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Triptorelin (Decapeptyl® SR) is recommended as an option for use within NHS Wales as an adjuvant treatment to radiotherapy in patients with high risk localised or locally advanced prostate cancer and as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download